Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Clifford J. Bailey, Stefano Del Prato, Cheryl Wei, Daniel Reyner, Gabriela Saraiva

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes'. Together they form a unique fingerprint.

Medicine & Life Sciences